Breaking News Instant updates and real-time market news.

MYOV

Myovant Sciences

$12.46

-4.87 (-28.10%)

, ABBV

AbbVie

$78.73

1.89 (2.46%)

12:31
05/14/19
05/14
12:31
05/14/19
12:31

Myovant Sciences selloff overdone after report of relugolix data, says Barclays

Barclays analyst Geoffrey Meacham said he thinks the selloff in shares of Myovant Sciences (MYOV) is overdone after the release of relugolix phase 3 uterine fibroids data. He believes investors are "selling the news" and he still believes relugolix has a comparable profile to AbbVie (ABBV) and Neurocrine's (NBIX) elagolix and will find a place in the market given what he sees as positive data reported this morning, Meacham tells investors. He keeps an Overweight rating and $25 price target on Myovant shares, which are down 26% to $12.67 in early afternoon trading.

MYOV

Myovant Sciences

$12.46

-4.87 (-28.10%)

ABBV

AbbVie

$78.73

1.89 (2.46%)

NBIX

Neurocrine

$77.92

1.66 (2.18%)

  • 14

    May

  • 18

    May

  • 22

    May

  • 31

    May

  • 05

    Jun

MYOV Myovant Sciences
$12.46

-4.87 (-28.10%)

04/11/19
EVER
04/11/19
INITIATION
Target $30
EVER
Outperform
Myovant Sciences initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Myovant Sciences (MYOV) with an Outperform rating and a price targets of $30. The analyst says the company's lead program relugolix has been clinically de-risked with near-term pivotal data readouts. Mehrotra is modeling revenues of $944M for the program by 2023 thanks to its "commercial advantage of a one-a-day pill" and the "second-mover leverage of competitor AbbVie's (ABBV) efforts to raise awareness and diagnosis" in woman's health market.
02/13/19
02/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Piyush Sood saying his firm's Metals & Mining team expects copper market tightness to emerge beginning in Q2, given falling global production, low visible inventories and improved demand from China and Freeport's earnings sensitivity to copper is still the highest among its peers. 2. DocuSign (DOCU) upgraded to Buy from Hold at Deutsche Bank with analyst Karl Keirstead saying that after speaking with four large e-signature customers, three using DocuSign and one using Adobe Sign, the analyst believes a "more constructive call on DocuSign shares is now warranted." 3. Bloom Energy (BE) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying shares are down about 36% since the IPO in July 2018, including a 24% drop since mid-January, the latter due in large part to selling pressure following lockup expiration. 4. Shopify (SHOP) upgraded to Outperform from Sector Perform at RBC Capital with analyst Ross MacMillan saying he anticipates the company to return to new merchant growth this year given its international opportunity and easier comps. 5. Myovant Sciences (MYOV) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying his firm's women's health survey suggests a "robust potential market" for new treatment options for endometriosis and uterine fibroids. The analyst also raised his price target for the shares to $25 from $22. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/19
LEHM
02/13/19
UPGRADE
Target $25
LEHM
Overweight
Barclays upgrades Myovant to Overweight on bullish women's health survey
Barclays analyst Geoffrey Meacham upgraded Myovant Sciences to Overweight from Equal Weight and raised his price target for the shares to $25 from $22. The analyst says his firm's women's health survey suggests a "robust potential market" for new treatment options for endometriosis and uterine fibroids. Respondents to the survey reported positive experiences with Orilissa and noted increasing patient interest in new therapies, Meacham tells investors in a research note. He believes Myovant will benefit from these market dynamics.
02/13/19
LEHM
02/13/19
UPGRADE
Target $25
LEHM
Overweight
Myovant Sciences upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham upgraded Myovant Sciences to Overweight and raised his price target for the shares to $25 from $22.
ABBV AbbVie
$78.73

1.89 (2.46%)

03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
03/25/19
03/25/19
DOWNGRADE

Hold
AbbVie downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded AbbVie to Hold, saying its flagship program Humira "no longer looks invulnerable to competition from biosimilars in Europe and other overseas markets." The analyst notes that Humira is also faced with "indirect competition from newer drugs that have an alternative mechanism of action" compared to Humira's anti-TNF class. Toung further cites AbbVie's clinical setback with Venclexta, which highlights the risks for the company as it develops a pipeline aimed to offset the expected decline in Humira sales.
04/28/19
BMOC
04/28/19
UPGRADE
Target $79
BMOC
Market Perform
AbbVie upgraded to Market Perform from Underperform at BMO Capital
BMO Capital analyst Alex Arfaei upgraded AbbVie to Market Perform from Underperform and raised his price target for the shares to $79 from $71. The stock closed Friday up 29c to $79.70. The analyst says his bearish thesis has mostly materialized and that he's now more bullish on Skyrizi and Upa. AbbVie can leverage its rebates to secure superior access in the U.S. and drive "strong" launches, Arfaei tells investors in a research note. He believes after a flat 2019, Skyrizi, Upa, Imbruvica/Venclexta and Orilissa should drive 4%-6% revenue growth during 2020-2022. This should improve sentiment on shares of AbbVie, says the analyst.
NBIX Neurocrine
$77.92

1.66 (2.18%)

04/29/19
CANT
04/29/19
NO CHANGE
Target $127
CANT
Overweight
Neurocrine selloff an opportunity for 'several reasons,' says Cantor Fitzgerald
Neurocrine Biosciences recently traded lower as Ingrezza was put on updated 2019 National Preferred Formulary exclusions list that Express Scripts (ESRX) published, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. The analyst sees the selloff as an "opportunity for longer-horizon investors for several reasons." The exclusion is not immediate, and will also have little impact on Ingrezza sales as Express Scripts accounts for less than 1% of the drugs revenue, Duncan writes. He believes Ingrezza will continue to grow with "deepening penetration" of the tardive dyskinesia market as the "pharmaco-economic benefits continue to be realized." The analyst reiterates an Overweight rating on Neurocrine with a $127 price target.
04/26/19
EVER
04/26/19
NO CHANGE
EVER
Neurocrine shares defended at Evercore ISI
04/22/19
JPMS
04/22/19
UPGRADE
Target $106
JPMS
Overweight
JPMorgan upgrades Neurocrine to Overweight after 15% pullback
JPMorgan analyst Anupam Rama upgraded Neurocrine Biosciences to Overweight from Neutral and raised his price target for the shares to $106 from $100. The stock is down ~15% from the mid-January highs, Rama tells investors in a research note. The analyst, however, says his "multiple proprietary analyses" since January "underscore the solid fundamentals of Neurocrine," For example, his March U.S. tardive dyskinesia physician survey shows a preference for Ingrezza over Austedo, anticipated overall branded market growth, and Ingrezza continuing to gain dominant market share over the next 12-24 months. Further, Rama believes the Q1 consensus estimate for Ingrezza could be beatable.
04/22/19
JPMS
04/22/19
UPGRADE
Target $106
JPMS
Overweight
Neurocrine upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Neurocrine Biosciences to Overweight from Neutral and raised his price target for the shares to $106 from $100. The analyst cites "solid" fundamentals and the recent pullback in the shares for the upgrade.

TODAY'S FREE FLY STORIES

KSS

Kohl's

$55.53

-7.42 (-11.79%)

15:40
05/21/19
05/21
15:40
05/21/19
15:40
Downgrade
Kohl's rating change  »

Kohl's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

DWDP

DowDuPont

$32.01

0.99 (3.19%)

15:36
05/21/19
05/21
15:36
05/21/19
15:36
Conference/Events
DowDuPont to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

TOL

Toll Brothers

$38.40

0.88 (2.35%)

15:34
05/21/19
05/21
15:34
05/21/19
15:34
Options
Toll Brothers options imply 8.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

GEO

Geo Group

$22.01

0.18 (0.82%)

15:30
05/21/19
05/21
15:30
05/21/19
15:30
Options
Put spreads in Geo Group as a bearish position is adjusted »

Put spreads in Geo Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$55.88

-7.07 (-11.23%)

, AMZN

Amazon.com

$1,858.97

0.16 (0.01%)

15:26
05/21/19
05/21
15:26
05/21/19
15:26
Recommendations
Kohl's, Amazon.com, Planet Fitness analyst commentary at Jefferies »

Kohl's price target…

KSS

Kohl's

$55.88

-7.07 (-11.23%)

AMZN

Amazon.com

$1,858.97

0.16 (0.01%)

PLNT

Planet Fitness

$76.76

-1.01 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 03

    Jun

  • 06

    Jun

  • 24

    Jun

TSLA

Tesla

$205.05

-0.2 (-0.10%)

15:24
05/21/19
05/21
15:24
05/21/19
15:24
Periodicals
Tesla lowers base price of new Model S, Model X cars, Electrek reports »

Tesla cut the base price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

URBN

Urban Outfitters

$27.07

0.11 (0.41%)

15:19
05/21/19
05/21
15:19
05/21/19
15:19
Options
Urban Outfitters options imply 13.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 04

    Jun

WYNN

Wynn Resorts

$120.62

1.5 (1.26%)

15:17
05/21/19
05/21
15:17
05/21/19
15:17
Recommendations
Wynn Resorts analyst commentary  »

Wynn Resorts named as new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
05/21/19
05/21
15:17
05/21/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCX

OncoCyte

$5.08

-0.08 (-1.55%)

15:16
05/21/19
05/21
15:16
05/21/19
15:16
Hot Stocks
OncoCyte presents 'positive' results from R&D validation study of DetermaVu »

OncoCyte presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
05/21/19
05/21
15:16
05/21/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YPF

YPF

$15.35

(0.00%)

15:15
05/21/19
05/21
15:15
05/21/19
15:15
Options
YPF put volume heavy and directionally bearish »

Bearish flow noted in YPF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:10
05/21/19
05/21
15:10
05/21/19
15:10
General news
Treasury Market Summary »

Treasury Market Summary:…

JWN

Nordstrom

$37.82

0.36 (0.96%)

15:04
05/21/19
05/21
15:04
05/21/19
15:04
Options
Nordstrom options imply 11.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

EADSY

Airbus

$0.00

(0.00%)

15:03
05/21/19
05/21
15:03
05/21/19
15:03
Periodicals
Airbus CEO hints at launch of new A321 plane, Reuters says »

Airbus CEO Guillaume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPL

Texas Pacific Land Trust

$853.39

8.39 (0.99%)

15:02
05/21/19
05/21
15:02
05/21/19
15:02
Hot Stocks
Texas Pacific Land Trust files lawsuit against trustee Eric Oliver »

Texas Pacific Land Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$111.18

1.94 (1.78%)

15:00
05/21/19
05/21
15:00
05/21/19
15:00
Options
Lowe's options volume is 3X daily average ahead of earnings »

Lowe's options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 31

    May

MNK

Mallinckrodt

$9.55

-3.47 (-26.65%)

14:59
05/21/19
05/21
14:59
05/21/19
14:59
Recommendations
Mallinckrodt analyst commentary at Raymond James »

Mallinckrodt could lose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$85.97

-0.26 (-0.30%)

14:58
05/21/19
05/21
14:58
05/21/19
14:58
Hot Stocks
Philip Morris announces creation of new senior management team roles »

Philip Morris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

$25.41

-0.39 (-1.51%)

14:49
05/21/19
05/21
14:49
05/21/19
14:49
Options
Sea Limited options imply 14.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

AAPL

Apple

$187.49

4.43 (2.42%)

14:31
05/21/19
05/21
14:31
05/21/19
14:31
Periodicals
Apple expands keyboard repair program to include butterfly mechanism, Verge says »

Apple is updating its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

CC

Chemours

$23.77

1.35 (6.02%)

14:30
05/21/19
05/21
14:30
05/21/19
14:30
Options
5K Chemours Oct 16 - 20 put spreads bought for 92c as shares rally »

5K Chemours Oct 16 - 20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
05/21/19
05/21
14:25
05/21/19
14:25
Conference/Events
Cowen biotechnology analysts to hold an analyst/industry conference call »

Biotechnology Analysts…

QRVO

Qorvo

$62.14

0.84 (1.37%)

14:22
05/21/19
05/21
14:22
05/21/19
14:22
Recommendations
Qorvo analyst commentary at Oppenheimer »

Qorvo could be first to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PED

PEDEVCO Corp.

$2.02

-0.06 (-2.88%)

14:21
05/21/19
05/21
14:21
05/21/19
14:21
Hot Stocks
PEDEVCO Corp. announces sale of stock to SK Energy, two unaffiliated investors »

PEDEVCO Corp. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.